Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric RRMS MRI and pharmacokinetics study of dimethyl fumarate
2014-005003-24Phase 2Completed
- Sponsor
- Biogen
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Change in new or newly enlarging T2 hyperintense brain MRI lesions. Started Feb 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2014-005003-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005003-24.